Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GALT
GALT logo

GALT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Galectin Therapeutics Inc (GALT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
4.610
1 Day change
-0.43%
52 Week Range
7.130
Analysis Updated At
2026/07/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

GALT is not a strong buy right now for a beginner long-term investor, even with $50,000-$100,000 to invest. The stock shows some short-term strength, but the setup is not supported by recent news, financial momentum, or strong proprietary trading signals. For an impatient investor unwilling to wait for a better entry, this is still a hold rather than an immediate buy.

Technical Analysis

Price closed at 4.54, slightly above the previous close of 4.51, with recent regular-session strength of 4.16%. The MACD histogram is positive at 0.163, but it is contracting, which weakens bullish momentum. RSI_6 at 67.653 is elevated and near overbought territory rather than signaling a fresh entry. Moving averages are converging, suggesting the trend is not yet decisive. Key levels show resistance at 4.925 and 5.51, with support at 3.978 and 3.03. Overall, the chart is constructive but not a high-conviction breakout setup.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is bullish based on the low put-call ratios, showing more calls than puts in both open interest and volume. Open interest is heavily skewed toward calls, and today’s option activity is elevated versus recent averages, which suggests trader interest. However, implied volatility is very high at 121.97 and historical volatility is also elevated at 112.95, so the options market is pricing in large moves. The sentiment is positive, but this looks more like speculative interest than a clean long-term confirmation.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
1
Buy
9

Positive Catalysts

  • ["Bullish options positioning with low put-call ratios", "Recent price strength above the previous close", "MACD remains positive, indicating some underlying upward momentum", "Short-term pattern projection shows a possible 2.05% move higher over the next month"]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh catalyst driving the stock", "No recent significant hedge fund or insider buying", "No recent congress trading activity", "AI Stock Picker: no signal today", "SwingMax: no signal recently", "MACD histogram is contracting, suggesting momentum is fading", "RSI is elevated, reducing attractiveness of an immediate entry", "Financial snapshot was unavailable, so there is no evidence of current fundamental acceleration"]

Financial Performance

Latest quarter financials were not available because the financial snapshot returned an error. Because of that, there is no reliable evidence to confirm revenue or earnings growth trends from the latest quarter season. From the available data, there is no fundamental update strong enough to support an aggressive long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change trend was provided, so there is no visible recent Wall Street upgrade/downgrade momentum to rely on. Based on the available data, Wall Street appears neutral rather than strongly bullish. The pros are the constructive options sentiment and improving price action, while the cons are the lack of catalysts, missing financial detail, and no supportive insider, hedge fund, or congress buying.

Wall Street analysts forecast GALT stock price to rise
1 Analyst Rating
Wall Street analysts forecast GALT stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.630
sliders
Low
11
Averages
11
High
11
Current: 4.630
sliders
Low
11
Averages
11
High
11
H.C. Wainwright
Matthew Keller
Buy
maintain
$6 -> $11
AI Analysis
2025-12-17
Reason
H.C. Wainwright
Matthew Keller
Price Target
$6 -> $11
AI Analysis
2025-12-17
maintain
Buy
Reason
H.C. Wainwright analyst Matthew Keller raised the firm's price target on Galectin Therapeutics to $11 from $6 and keeps a Buy rating on the shares. The firm says recent biomarker data continue to strengthen confidence in Galectin's metabolic dysfunction-associated steatohepatitis program.

People Also Watch